Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients

MLA

Ichiro Nakajima, et al. “Single Fixed Low-Dose Rituximab as Induction Therapy Suppresses de Novo Donor-Specific Anti-HLA Antibody Production in ABO Compatible Living Kidney Transplant Recipients.” PLoS ONE, vol. 14, no. 10, Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1f96c46d55861b4dc3997943ff4ebf56&authtype=sso&custid=ns315887.

APA

Ichiro Nakajima, Katsuyuki Miki, Yuichi Ogawa, Kazuhiro Iwadoh, Akihito Sannomiya, Ichiro Koyama, Kotaro Kai, Kumiko Kitajima, Yusuke Tomita, Yojiro Kato, & Shohei Fuchinoue. (2019). Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients. PLoS ONE, 14(10).

Chicago

Ichiro Nakajima, Katsuyuki Miki, Yuichi Ogawa, Kazuhiro Iwadoh, Akihito Sannomiya, Ichiro Koyama, Kotaro Kai, et al. 2019. “Single Fixed Low-Dose Rituximab as Induction Therapy Suppresses de Novo Donor-Specific Anti-HLA Antibody Production in ABO Compatible Living Kidney Transplant Recipients.” PLoS ONE 14 (10). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1f96c46d55861b4dc3997943ff4ebf56&authtype=sso&custid=ns315887.